Item 2.02 Results of Operations and Financial Condition.

The information provided in Item 7.01 of this Current Report on Form 8-K is incorporated in this Item 2.02 by reference.

Item 7.01 Regulation FD Disclosure.

On May 15, 2023, TherapeuticsMD, Inc., a Nevada corporation (the "Company"), issued a press release announcing its financial results for the quarter ended March 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01 and the information contained in Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in any such filing, regardless of any general incorporation language in the filing.

The Company does not have, and expressly disclaims, any obligation to release publicly any updates or any changes in its expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.

                                 Exhibit Index

Exhibit No.       Description

99.1                Press Release from TherapeuticsMD, Inc., dated May 15, 2023,
                  entitled "TherapeuticsMD Announces First Quarter 2023 Financial
                  Results"

104               Cover Page Interactive Data File (the cover page tags are
                  embedded within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses